WallStreetZenWallStreetZen

NASDAQ: ORIC
Oric Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for ORIC

Based on 5 analysts offering 12 month price targets for Oric Pharmaceuticals Inc

Min Forecast
$12.00+13.21%
Avg Forecast
$16.20+52.83%
Max Forecast
$19.00+79.25%

Should I buy or sell ORIC stock?

Based on 5 analysts offering ratings for Oric Pharmaceuticals Inc.

Strong Buy
Strong Buy
3 analysts 60%
Buy
2 analysts 40%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although ORIC's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates ORIC as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their ORIC stock forecasts and price targets.

ORIC stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-08-14
lockedlocked$00.00+00.00%2025-08-14
lockedlocked$00.00+00.00%2025-08-13
lockedlocked$00.00+00.00%2025-07-08
lockedlocked$00.00+00.00%2025-05-06

1 of 1

Forecast return on equity

Is ORIC forecast to generate an efficient return?

Company
-46.91%
Industry
122.18%
Market
-52.22%
ORIC's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ORIC forecast to generate an efficient return on assets?

Company
-43.82%
Industry
46.05%
ORIC is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ORIC earnings per share forecast

What is ORIC's earnings per share in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
-$1.72
Avg 2 year Forecast
-$1.68
Avg 3 year Forecast
-$1.69

ORIC revenue forecast

What is ORIC's revenue in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
$29.7M
Avg 2 year Forecast
$91.6M
Avg 3 year Forecast
$339.5M

ORIC vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ORIC$10.60$16.20+52.83%Strong Buy
SYRE$16.81$45.00+167.70%Buy
MDXG$7.10$12.00+69.01%Strong Buy
NUVB$3.15$7.60+141.27%Buy
ZYME$14.14$17.50+23.76%Buy
View Top Biotech Stocks

Oric Pharmaceuticals Stock Forecast FAQ

Is Oric Pharmaceuticals Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: ORIC) stock is to Strong Buy ORIC stock.

Out of 5 analysts, 3 (60%) are recommending ORIC as a Strong Buy, 2 (40%) are recommending ORIC as a Buy, 0 (0%) are recommending ORIC as a Hold, 0 (0%) are recommending ORIC as a Sell, and 0 (0%) are recommending ORIC as a Strong Sell.

If you're new to stock investing, here's how to buy Oric Pharmaceuticals stock.

What is ORIC's earnings growth forecast for 2025-2027?

(NASDAQ: ORIC) Oric Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.22%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 14.9%.

Oric Pharmaceuticals's earnings in 2025 is -$137,249,000.On average, 7 Wall Street analysts forecast ORIC's earnings for 2025 to be -$167,187,510, with the lowest ORIC earnings forecast at -$192,303,514, and the highest ORIC earnings forecast at -$155,396,779. On average, 7 Wall Street analysts forecast ORIC's earnings for 2026 to be -$163,302,590, with the lowest ORIC earnings forecast at -$208,814,422, and the highest ORIC earnings forecast at -$146,655,710.

In 2027, ORIC is forecast to generate -$164,458,354 in earnings, with the lowest earnings forecast at -$178,706,296 and the highest earnings forecast at -$151,511,860.

What is ORIC's revenue growth forecast for 2028-2030?

(NASDAQ: ORIC) Oric Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 82.88%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.63%.

Oric Pharmaceuticals's revenue in 2025 is $0.On average, 2 Wall Street analysts forecast ORIC's revenue for 2028 to be $2,880,667,794, with the lowest ORIC revenue forecast at $1,476,269,402, and the highest ORIC revenue forecast at $4,285,066,186. On average, 1 Wall Street analysts forecast ORIC's revenue for 2029 to be $8,894,523,149, with the lowest ORIC revenue forecast at $8,894,523,149, and the highest ORIC revenue forecast at $8,894,523,149.

In 2030, ORIC is forecast to generate $32,968,397,937 in revenue, with the lowest revenue forecast at $32,968,397,937 and the highest revenue forecast at $32,968,397,937.

What is ORIC's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: ORIC) forecast ROA is -43.82%, which is lower than the forecast US Biotechnology industry average of 46.05%.

What is ORIC's Price Target?

According to 5 Wall Street analysts that have issued a 1 year ORIC price target, the average ORIC price target is $16.20, with the highest ORIC stock price forecast at $19.00 and the lowest ORIC stock price forecast at $12.00.

On average, Wall Street analysts predict that Oric Pharmaceuticals's share price could reach $16.20 by Aug 14, 2026. The average Oric Pharmaceuticals stock price prediction forecasts a potential upside of 52.83% from the current ORIC share price of $10.60.

What is ORIC's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: ORIC) Oric Pharmaceuticals's current Earnings Per Share (EPS) is -$1.89. On average, analysts forecast that ORIC's EPS will be -$1.72 for 2025, with the lowest EPS forecast at -$1.98, and the highest EPS forecast at -$1.60. On average, analysts forecast that ORIC's EPS will be -$1.68 for 2026, with the lowest EPS forecast at -$2.15, and the highest EPS forecast at -$1.51. In 2027, ORIC's EPS is forecast to hit -$1.69 (min: -$1.84, max: -$1.56).

What is ORIC's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: ORIC) forecast ROE is -46.91%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.